Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New Ingredients, New Life For Cytodyne’s Weight Loss Supplements

This article was originally published in The Tan Sheet

Executive Summary

A firm that has agreed to pay as much as $12.8 million to settle a false advertising complaint and that reorganized under bankruptcy protection after incurring losses from ephedra-related lawsuits is returning to the marketplace with a new weight loss supplement, according to a Jan. 15 announcement

You may also be interested in...



Supreme Court Refuses Ephedra Case, Battle Against Risk-Benefit Continues

Challenges to the risk-benefit analysis FDA applied in banning the use of ephedra will continue following the Supreme Court's May 14 refusal to hear Nutraceutical Corp.'s appeal, according to the firm's attorney and to industry trade groups

FTC Supplement Settlements Spotlight Bayer, Mark First Hoodia Action

Bayer "went too far" with weight-loss and -control claims for its One-A-Day WeightSmart product and violated a 1991 sanction the product's previous owner agreed to, the Federal Trade Commission said Jan. 4 when it announced a record $3.2 million fine against the consumer healthcare giant

US FDA Allows Supplement Firms More Time To Submit NDI Notifications, And For It To Respond

More time for notifications than current deadline of at least 75 days before NDI-containing product is offered for sale in US doesn’t solve problems with FDA’s management of NDI regulation, say trade groups.

Topics

UsernamePublicRestriction

Register

PS101348

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel